Antiangiogenic Factors in Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00735566
Recruitment Status : Completed
First Posted : August 15, 2008
Last Update Posted : October 18, 2012
Information provided by (Responsible Party):
Jun Ho Lee, National Cancer Center, Korea

Brief Summary:
Endogenous antiangiogenic factors are related with gastric cancer progression.

Condition or disease
Gastric Cancer

Detailed Description:
Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.

Study Type : Observational
Actual Enrollment : 240 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression
Study Start Date : April 2006
Actual Primary Completion Date : July 2008
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
U.S. FDA Resources

Primary Outcome Measures :
  1. Relationship between antiangiogenic factor and tumor, node, metastasis [ Time Frame: One year ]

Secondary Outcome Measures :
  1. Overall survival, treatment failure [ Time Frame: 5 years ]

Biospecimen Retention:   Samples Without DNA
Serum for protein assay using ELISA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Eligible patients will undergo subtotal or total gastrectomy with D2 lymph node dissection

Inclusion Criteria:

  • Histologic diagnosis of gastric adenocarcinoma
  • No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study
  • Performance status of 0, 1, 2 on the ECOG criteria
  • ASA class I, II
  • Patient compliance that allow adequate follow up
  • Informed consent from patient or patient's relative.

Exclusion Criteria:

  • Second primary malignancy
  • EMR (Endoscopic mucosal resection) indication
  • Laparoscopic gastrectomy
  • Radiologic or clinical evidence of metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00735566

Korea, Republic of
National Cancer Center
Goyang-si, Geonggi-do, Korea, Republic of, 410-0769
Sponsors and Collaborators
National Cancer Center, Korea
Principal Investigator: Jun Ho Lee, M.D., Ph.D Gastric Cancer Branch, National Cancer Center

Responsible Party: Jun Ho Lee, Staff Surgeon, National Cancer Center, Korea Identifier: NCT00735566     History of Changes
Other Study ID Numbers: NCCCTS 04-105
First Posted: August 15, 2008    Key Record Dates
Last Update Posted: October 18, 2012
Last Verified: October 2012

Keywords provided by Jun Ho Lee, National Cancer Center, Korea:
gastric cancer
antiangiogenic factors
TNM stage

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents